<DOC>
	<DOC>NCT01742429</DOC>
	<brief_summary>To test the efﬁcacy of 14 day levoﬂoxacin and bismuth-containing second-line therapy for resistant Helicobacter pylori infection, to compare with the classical quadruple therapy.</brief_summary>
	<brief_title>Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth subsalicylate</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>all patients had failed H.pylori therapies including clarithromycin, metronidazole and/or amoxicillin (if not allergic) before. patients less than 18 years old, previous gastric surgery, pregnancy, lactation, major systemic diseases, administration of antibiotics, bismuth, antisecretory drugs in the preceding 8 weeks, or allergy to any one of the medication used in the quadruple regimens.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Helicobacter pylori</keyword>
	<keyword>second line treatment</keyword>
</DOC>